These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36814107)

  • 1. Is the fundamental pathology in Duchenne's muscular dystrophy caused by a failure of glycogenolysis-glycolysis in costameres?
    Nesari V; Balakrishnan S; Nongthomba U
    J Genet; 2023; 102():. PubMed ID: 36814107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
    Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disrupted Calcium Homeostasis in Duchenne Muscular Dystrophy: A Common Mechanism behind Diverse Consequences.
    Zabłocka B; Górecki DC; Zabłocki K
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unusually severe muscular dystrophy upon in-frame deletion of the dystrophin rod domain and lack of compensation by membrane-localized utrophin.
    Gorokhova S; Schessl J; Zou Y; Yang ML; Heydemann PT; Sufit RL; Meilleur K; Donkervoort S; Medne L; Finkel RS; Bönnemann CG
    Med; 2023 Apr; 4(4):245-251.e3. PubMed ID: 36905929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic analysis of the sarcolemma-enriched fraction from dystrophic mdx-4cv skeletal muscle.
    Murphy S; Zweyer M; Henry M; Meleady P; Mundegar RR; Swandulla D; Ohlendieck K
    J Proteomics; 2019 Jan; 191():212-227. PubMed ID: 29408692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.
    Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC
    Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striated muscle activator of Rho signalling (STARS) overexpression in the mdx mouse enhances muscle functional capacity and regulates the actin cytoskeleton and oxidative phosphorylation pathways.
    Sadler KJ; Gatta PAD; Naim T; Wallace MA; Lee A; Zaw T; Lindsay A; Chung RS; Bello L; Pegoraro E; Lamon S; Lynch GS; Russell AP
    Exp Physiol; 2021 Jul; 106(7):1597-1611. PubMed ID: 33963617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficiency of dystrophin-associated proteins in Duchenne muscular dystrophy patients lacking COOH-terminal domains of dystrophin.
    Matsumura K; Tomé FM; Ionasescu V; Ervasti JM; Anderson RD; Romero NB; Simon D; Récan D; Kaplan JC; Fardeau M
    J Clin Invest; 1993 Aug; 92(2):866-71. PubMed ID: 8349821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic
    Wong TWY; Ahmed A; Yang G; Maino E; Steiman S; Hyatt E; Chan P; Lindsay K; Wong N; Golebiowski D; Schneider J; Delgado-Olguín P; Ivakine EA; Cohn RD
    Dis Model Mech; 2020 Sep; 13(9):. PubMed ID: 32988972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
    Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
    Guiraud S; Edwards B; Squire SE; Moir L; Berg A; Babbs A; Ramadan N; Wood MJ; Davies KE
    Hum Mol Genet; 2019 Jan; 28(2):307-319. PubMed ID: 30304405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ion Channels of the Sarcolemma and Intracellular Organelles in Duchenne Muscular Dystrophy: A Role in the Dysregulation of Ion Homeostasis and a Possible Target for Therapy.
    Dubinin MV; Belosludtsev KN
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel high-throughput immunofluorescence analysis method for quantifying dystrophin intensity in entire transverse sections of Duchenne muscular dystrophy muscle biopsy samples.
    Sardone V; Ellis M; Torelli S; Feng L; Chambers D; Eastwood D; Sewry C; Phadke R; Morgan JE; Muntoni F
    PLoS One; 2018; 13(3):e0194540. PubMed ID: 29579078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased dysferlin expression in Duchenne muscular dystrophy.
    Vontzalidis A; Terzis G; Manta P
    Anal Quant Cytopathol Histpathol; 2014 Feb; 36(1):15-22. PubMed ID: 24902367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle.
    Klymiuk N; Blutke A; Graf A; Krause S; Burkhardt K; Wuensch A; Krebs S; Kessler B; Zakhartchenko V; Kurome M; Kemter E; Nagashima H; Schoser B; Herbach N; Blum H; Wanke R; Aartsma-Rus A; Thirion C; Lochmüller H; Walter MC; Wolf E
    Hum Mol Genet; 2013 Nov; 22(21):4368-82. PubMed ID: 23784375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo revertant fiber formation and therapy testing in a 3D culture model of Duchenne muscular dystrophy skeletal muscle.
    Ebrahimi M; Lad H; Fusto A; Tiper Y; Datye A; Nguyen CT; Jacques E; Moyle LA; Nguyen T; Musgrave B; Chávez-Madero C; Bigot A; Chen C; Turner S; Stewart BA; Pegoraro E; Vitiello L; Gilbert PM
    Acta Biomater; 2021 Sep; 132():227-244. PubMed ID: 34048976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
    Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
    Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic remodeling of dystrophic skeletal muscle reveals biological roles for dystrophin and utrophin in adaptation and plasticity.
    Hardee JP; Martins KJB; Miotto PM; Ryall JG; Gehrig SM; Reljic B; Naim T; Chung JD; Trieu J; Swiderski K; Philp AM; Philp A; Watt MJ; Stroud DA; Koopman R; Steinberg GR; Lynch GS
    Mol Metab; 2021 Mar; 45():101157. PubMed ID: 33359740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.